You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB06186
DescriptionIpilimumab, a recombinant human monoclonal antibody (IgG1 kappa immunoglobin), is an antineoplastic agent developed by Bristol-Myers Squibb and Medarex for the treatment of unresectable or metastatic melanoma in adults. Ipilimumab received FDA approved on March 25, 2011. In October 2015, the FDA approved expanded the indications for Ipilimumab, allowing it to be used to reduce the risk of the deadly skin cancer returning after surgery.
Protein structureDb06186
Related Articles
Protein chemical formulaC6572H10126N1734O2080S40
Protein average weight148000.0 Da
>Ipilimumab heavy chain (patent appl. US20150283234) 
>Ipilimumab light chain 
Download FASTA Format
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
YervoyLiquid5 mgIntravenousBristol Myers Squibb2012-03-08Not applicableCanada
YervoyInjection5 mg/mLIntravenousE.R. Squibb & Sons, L.L.C.2011-03-25Not applicableUs
YervoyInjection5 mg/mLIntravenousE.R. Squibb & Sons, L.L.C.2011-03-25Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CAS number477202-00-9
IndicationIpilimumab is indicated for the treatment of unresectable or metastatic melanoma in adults. It is also used to reduce the risk of the deadly skin cancer returning after surgery.
Structured Indications
Clinical Trials
0Active Not RecruitingTreatmentMelanoma1
1Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Lymphoma, B Cell1
1Active Not RecruitingTreatmentAdvanced Tumor / Metastatic Tumors1
1Active Not RecruitingTreatmentCastrate Resistant Prostate Cancer (CRPC) / Prostate Cancers1
1Active Not RecruitingTreatmentMalignant Melanoma1
1Active Not RecruitingTreatmentMelanoma2
1Active Not RecruitingTreatmentMelanoma (Skin)1
1Active Not RecruitingTreatmentRecurrent Melanoma / Stage IV Melanoma / Tumors Metastatic to Brain1
1Active Not RecruitingTreatmentUnresectable Melanoma1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Childhood Myelodysplastic Syndromes / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Disseminated Neuroblastoma / Neoplasms, Malignant / Ovarian Choriocarcinoma / Ovarian Embryonal Carcinoma / Ovarian Immature Teratoma / Ovarian Mature Teratoma / Ovarian Mixed Germ Cell Tumor / Ovarian Monodermal and Highly Specialized Teratoma / Ovarian Polyembryoma / Ovarian Yolk Sac Tumor / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Neuroblastoma / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage II Ovarian Epithelial Cancer / Stage III Malignant Testicular Germ Cell Tumor / Stage III Multiple Myeloma / Stage III Ovarian Epithelial Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Ovarian Epithelial Cancer / Testicular Choriocarcinoma / Testicular Choriocarcinoma and Embryonal Carcinoma / Testicular Choriocarcinoma and Seminoma / Testicular Choriocarcinoma and Teratoma / Testicular Choriocarcinoma and Yolk Sac Tumor / Testicular Embryonal Carcinoma / Testicular Embryonal Carcinoma and Seminoma / Testicular Embryonal Carcinoma and Teratoma / Testicular Embryonal Carcinoma and Teratoma With Seminoma / Testicular Embryonal Carcinoma and Yolk Sac Tumor / Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma / Testicular Teratoma / Testicular Yolk Sac Tumor / Testicular Yolk Sac Tumor and Teratoma / Testicular Yolk Sac Tumor and Teratoma With Seminoma1
1CompletedTreatmentAdvanced Melanoma1
1CompletedTreatmentLymphoma NOS / Neuroblastomas / Sarcomas / Wilms' tumor1
1CompletedTreatmentPancreatic Cancers1
1CompletedTreatmentProstatic Neoplasms1
1CompletedTreatmentSolid Tumours1
1CompletedTreatmentTransitional Cell Carcinoma1
1Not Yet RecruitingTreatmentAdvanced Cancers / Melanoma1
1Not Yet RecruitingTreatmentMelanoma1
1Not Yet RecruitingTreatmentMelanoma / Sarcomas1
1Not Yet RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1RecruitingNot AvailableMelanoma1
1RecruitingBasic ScienceAdvanced Melanoma / Metastatic Melanoma1
1RecruitingBasic ScienceMelanoma1
1RecruitingTreatmentAdvanced Cancers2
1RecruitingTreatmentAdverse Effect of Radiation Therapy / Effects of Immunotherapy / Melanoma1
1RecruitingTreatmentMelanoma / Skin Cancers1
1RecruitingTreatmentMetastatic Melanoma2
1RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentProstate Cancers1
1RecruitingTreatmentSolid Cancers1
1TerminatedTreatmentMalignant Melanoma1
1TerminatedTreatmentProstate Cancers1
1, 2Active Not RecruitingTreatmentMelanoma1
1, 2Active Not RecruitingTreatmentMetastatic Melanoma2
1, 2Active Not RecruitingTreatmentProstate Cancers1
1, 2CompletedTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentNeoplasms Metastasis / Prostate Cancers1
1, 2CompletedTreatmentUnresectable Stage III or IV Malignant Melanoma1
1, 2Not Yet RecruitingTreatmentImmunotherapy / Neoplasms, Head and Neck1
1, 2Not Yet RecruitingTreatmentLymphoma NOS / Multiple Myeloma (MM)1
1, 2Not Yet RecruitingTreatmentMetastatic Brain Cancer1
1, 2Not Yet RecruitingTreatmentProstate Cancers1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentCancers1
1, 2RecruitingTreatmentHepatocellular Carcinomas1
1, 2RecruitingTreatmentLiver Cancer / Lung Cancers1
1, 2RecruitingTreatmentLymphoma NOS / Tumors, Solid1
1, 2RecruitingTreatmentMSI Negative Colorectal Cancer / MSI Positive Colorectal Cancer1
1, 2RecruitingTreatmentMalignant Melanoma1
1, 2RecruitingTreatmentMelanoma2
1, 2RecruitingTreatmentMelanoma / Metastatic (Stage IV) Melanoma / Unresectable (Stage III) Melanoma1
1, 2RecruitingTreatmentMetastatic Melanoma2
1, 2RecruitingTreatmentMetastatic Melanoma / Stage III Melanoma / Stage IV Melanoma1
1, 2RecruitingTreatmentStage III or IV Melanoma1
1, 2RecruitingTreatmentUnresectable Stage III or Stage IV Melanoma1
1, 2RecruitingTreatmentVarious Advanced Cancer1
1, 2TerminatedTreatmentMelanoma1
1, 2WithdrawnTreatmentMelanoma2
1, 2WithdrawnTreatmentMetastatic Melanoma1
2Active Not RecruitingTreatmentCarcinoma, Urothelial1
2Active Not RecruitingTreatmentMetastatic Melanoma2
2Active Not RecruitingTreatmentMetastatic Melanoma / Unresectable Melanoma1
2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentProstate Cancers2
2CompletedTreatmentAdenocarcinomas / Cancer, Breast1
2CompletedTreatmentBrain Metastasis / Melanoma1
2CompletedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) / Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentMalignant Melanoma2
2CompletedTreatmentMetastatic Malignant Melanoma1
2CompletedTreatmentOcular Melanoma1
2CompletedTreatmentProstate Cancers1
2Not Yet RecruitingTreatmentAcral lentiginous melanoma / Mucosal Melanoma1
2Not Yet RecruitingTreatmentMelanoma1
2Not Yet RecruitingTreatmentMesothelioma1
2Not Yet RecruitingTreatmentMetastatic Melanoma1
2Not Yet RecruitingTreatmentProstate Cancers1
2Not Yet RecruitingTreatmentProstatic Neoplasms1
2Not Yet RecruitingTreatmentUveal Melanoma1
2RecruitingTreatmentIn-transit Metastases Melanoma Stage IIIB and IIIC1
2RecruitingTreatmentLeukemias / Myelodysplastic Syndrome1
2RecruitingTreatmentLimited Stage Small Cell Lung Cancer / Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentMalignant Melanoma1
2RecruitingTreatmentMalignant Melanoma Stage III1
2RecruitingTreatmentMelanoma / Metastases, Brain2
2RecruitingTreatmentMelanoma / Oligometastatic Melanoma1
2RecruitingTreatmentMelanoma / Uveal Melanoma1
2RecruitingTreatmentMetastases, Brain / Metastatic Melanoma1
2RecruitingTreatmentMetastatic Castration Sensitive Prostate Cancer1
2RecruitingTreatmentMetastatic Melanoma / Stage IV Melanoma1
2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
2RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
2RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentProstate Cancers2
2TerminatedTreatmentMetastatic Melanoma2
2WithdrawnTreatmentNeuroendocrine Carcinoma of the Skin1
2WithdrawnTreatmentProstate Cancers1
3Active Not RecruitingTreatmentHigh Risk Stage III Melanoma1
3Active Not RecruitingTreatmentLung Cancer - Non Small Cell1
3Active Not RecruitingTreatmentMelanoma1
3CompletedTreatmentMelanoma / Metastases1
3CompletedTreatmentProstate Cancers2
3RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Cancer1
3RecruitingTreatmentLung Cancers1
3RecruitingTreatmentMetastases, Brain1
3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentOcular Melanoma1
4Active Not RecruitingTreatmentMalignant Melanoma1
4RecruitingTreatmentRenal Cell Carcinoma (RCC)1
4TerminatedTreatmentMetastatic Melanoma1
Not AvailableAvailableNot AvailableMalignant Melanoma1
Not AvailableCompletedNot AvailableAdvanced Melanoma1
Not AvailableCompletedNot AvailableMelanoma1
Not AvailableNo Longer AvailableNot AvailableMelanoma1
Not AvailableRecruitingNot AvailableMelanoma2
Not AvailableRecruitingTreatmentBlood And Marrow Transplantation / Leukemias / Lymphoma NOS1
Not AvailableRecruitingTreatmentKidney Cancer1
Not AvailableRecruitingTreatmentMelanoma1
Not AvailableRecruitingTreatmentMetastatic Melanoma1
PharmacodynamicsThe pharmacodynamics of Ipilimumab are not completely understood. In melanoma patients receiving Ipilimumab, the mean peripheral blood absolute lymphocyte counts (ALC) increased throughout the induction dosing period. This increase occurred in a dose-dependent fashion in Phase 2 studies. Ipilimumab given with or without gp100 at 3 mg/kg increased ALC throughout the induction dosing period, but no meaningful change in ALC occurred in the control group who received an investigational peptide vaccine alone. Furthermore, ipilimumab binds to CTLA-4 with high affinity (Kd = 5.24 ± 3.62 nM). As a result, ligands CD80 and CD86 are blocked from binding to CTLA-4 with a minimum EC50 value of 0.2 μg/mL.
Mechanism of actionIpilimumab is a fully human IgG1κ antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system's T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be through T-cell - mediated anti-tumor immune responses.
TargetKindPharmacological actionActionsOrganismUniProt ID
Cytotoxic T-lymphocyte protein 4ProteinyesNot AvailableHumanP16410 details
Related Articles
AbsorptionIn one pharmacokinetic study of patients with unresectable or metastatic melanoma peak concentrations, trough concentrations, and area under the curve (AUC) were found to be dose proportional in the dosage range examined (0.3, 3, or 10mg/kg every 3 weeks for four doses).
Volume of distribution

Volume of distribution at steady state = 7.21 L

Protein bindingNot Available

The metabolism of ipilimumab does not involve the cytochrome P450 enzyme system. Because ipilimumab is a protein it is expected to be degraded into small peptides and amino acids by proteolytic enzymes.

Route of eliminationNot Available
Half lifeTerminal Elimination Half-life: 14.7 -15.4 days

Clearance was measured to be 15.3mL/hr-16.8 mL/hr.

In one pharmacokinetic study examining ipilimumab administered every 3 weeks, clearance was found to be time invariant. Minimal systemic accumulation was observed (accumulation index of 1.5 fold or less).
Steady state concentrations was reached by the third dose.

Clearance will increase with increasing body weight; however, no dose adjustment is needed if administration occurs on a mg/kg basis. The following had no clinically meaningful influence on clearance: Age (range 26-86 years), gender, creatinine clearance (if ≥29ml/min), baseline AST, total bilirubin, ALT levels, concomitant use of budesonide, performance status, HLA-A2*0201 status, positive anti-ipilimumab antibody status, prior use of systemic anticancer therapy, baseline lactate dehydrogenase levels.

ToxicityTherapy with Ipilimumab can result in severe and fatal immune reactions due to T-cell proliferation and activation. These reactions may occur in multiple organ systems, but common reactions include enterecolitis, dermatitis (including toxic necrolysis), neuropathy, and endocrinopathy. Patients should be assessed for signs and symptoms of enterocolitis (diarrhea, abdominal pain, mucus/blood in stool), bowel perforation (petitoneal signs and ileus), hepatitis, dermatitis (rash and pruritus), motor or sensory neuropathy (unilateral/bilateral weakness, sensory alterations, or paresthesia) , hypophysitis/adrenal insufficiency including adrenal crisis/hyper- or hypothyroidism (fatigue, mental status change, abdominal pain, unusual bowel habits, hypotension) and should have liver function tests and thyroid function tests performed at baseline and prior to each dose. Typically immune mediated adverse reactions manifest during therapy, however, a minority of reactions occurred after discontinuation of ipilimumab. In one study of neuropathies, one case of fatal Guillain-Barré syndrome occurred, and once case of severe peripheral neuropathy (Grade 3) was reported. During clinical development of ipilimumab additional cases of Guillain-Barré and myasthenia gravis have been reported. In severe neuropathy, permanently discontinue ipilimumab, and initiate 1-2mg/kd/day of prednisone or equivalent. In one study, severe or potentially fatal dermatitis (eg, Steven-Johnsons syndrome (SJS) or toxic epidermal necrolysis (TEN)) occured in 2.5% (n=13). The median time of onset of moderate to potentially fatal dermatitis was 3.1 weeks (up to 17.3 weeks). Treatment of 54% of severe dermatitis cases (n=7) involved high dose topical corticosteriods. 6 patients had complete resolution in up to 15.6 weeks. Permanently discontinue ipilimumab in patients with SJS or TEN, and withhold the dose in patients with moderate to severe signs and symptoms. Mild- moderate dermatitis (localized rash and pruritus) may be treated symptomatically. If no improvement is seen in 1 week administer topical or systemic corticosteroids. In one study of endocrinopathies, severe to life threatening endocrinopathies occurred in 1.8% (n=9) of patients, with all 9 patients having hyopituitarism and some having adrenal insufficiency, hypogonadism, and hypothyroidism. Six of the 9 patients were hospitalized. Moderate endocrinopathies occurred in 2.3% of patients (n=12) and required hormone replacement or medical intervention. The median time of onset was 11 weeks. In symptomatic patients, withhold ipilimumab, and initiate 1-2mg/kd/day of prednisone or equivalent and appropriate hormone replacement therapy. In one study of enterocolitis in 511 patients, diarrhea of ≥7 stools above baseline, fever, ileus and peritoneal signs (Grade 3-5, severe, potentially fatal enterocolitis) occured in 7% (n=34) of patients treated with ipilimumab. Diarrhea of up to 6 stools above baseline, abdominal pain, mucus or blood in stool (Grade 2, moderate enterocolitis) occurred in 5% of patients (n=28). Intestinal perforation occurred in 1% (n=5). Death as a result of complications occurred in 0.8% (n=4). Hospitalization for severe enterocolitis occurred in 5% (n=26). Grade 3-5 enterocolitis had a median time of onset of 7.4 weeks (with a range of 1.6-13.4 weeks). Grade 2 entercolitis had a median time of onset of 6.3 weeks (with a range of 0.3- 18.9 weeks). Treatment of 85% (n=29) of patients with Grade 3-5 enterocolitis (n=34) included high dose corticosteroids (≥40mg/day prednisone equivalent). Median dose used was 80mg/day of prednisone/equivalent for a median duration of 2.3 weeks (up to 13.9 weeks). Of the 34 patients, 74% experienced complete resolution, 3% progressed to Grade 2 severity, and 24% exhibited no improvement. In treatment of 28 patients with a Grade 2 enterocolitis: 25% received high dose corticosteroids for a median of 10 days; 29% of patients received a non-high dose of corticosteroids (<40mg/day of prednisone/equivalent) for a median duration of 5.1 weeks; 46% did not receive systemic corticosteroids. Of the 28 patients, 79% of patients experienced complete resolution, 11% improved in severity, 11% exhibited no improvement. In patients with severe enterocolitis, permanently discontinue ipilimumab, and initiate 1-2 mg/kd/day of prednisone or an equivalent. Once patient improvement to Grade 1 or less is seen, taper the corticosteroid over at least one month. In patients with moderate enterocolitis, hold dose of ipilimumab, and initiate 0.5 mg/kd/day of prednisone or an equivalent. In another study examining immune mediated hepatitis, AST or ALT elevation of ≥3 times the upper limit of normal (ULN) (severe and potentially fatal hepatotoxicity) was seen in 2% (n=8) of patients on ipilimumab. Fatal hepatic failure occurred in 0.2%. Hospitalization occurred in 0.4%. Additionally, moderate hepatotoxicity (2.5xULN >ALT or AST> 5xULN, or 1.5xULN>bilirubin>3xULN ) occurred in 2.5% (n=13). In Grade 3-5 hepatotoxicity, permanently discontinue ipilimumab, and initiate 1-2mg/kd/day of prednisone or equivalent. Once LFT show sustained improvement taper corticosteroid over 1 month. In Grade 2 hepatotoxicity, withhold ipilimumab. In pregnancy, use only if potential benefit justifies potential risk to fetus (Category C). In studies done in monkeys, severe toxicities were observed including abortion, stillbirth, low birth weight and infant mortality. Additionally, ipilimumab has the potential to cross the placental barrier, and it is unknown if secretion into breast milk occurs. No studies have been performed to study carcinogenesis, mutagenesis, and impairment of fertility.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ipilimumab.Approved
ALT-110The therapeutic efficacy of ALT-110 can be decreased when used in combination with Ipilimumab.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Ipilimumab.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Ipilimumab is combined with Belimumab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ipilimumab.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ipilimumab.Approved
CDX-110The therapeutic efficacy of CDX-110 can be decreased when used in combination with Ipilimumab.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ipilimumab.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ipilimumab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ipilimumab.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Ipilimumab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ipilimumab.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Ipilimumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ipilimumab.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Ipilimumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ipilimumab.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Ipilimumab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ipilimumab.Approved, Vet Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Ipilimumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ipilimumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Ipilimumab.Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ipilimumab.Approved, Investigational
VemurafenibIpilimumab may increase the hepatotoxic activities of Vemurafenib.Approved
Food InteractionsNot Available
Synthesis ReferenceNot Available
General References
  1. Ribas A: Tumor immunotherapy directed at PD-1. N Engl J Med. 2012 Jun 28;366(26):2517-9. doi: 10.1056/NEJMe1205943. Epub 2012 Jun 2. [PubMed:22658126 ]
External Links
ATC CodesL01XC11
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (374 KB)
MSDSDownload (479 KB)
ManufacturersNot Available
PackagersNot Available
Dosage forms
InjectionIntravenous5 mg/mL
LiquidIntravenous5 mg
PricesNot Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2381770 No2007-08-072020-08-08Canada
Experimental PropertiesNot Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available


Pharmacological action
General Function:
Not Available
Specific Function:
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Gene Name:
Uniprot ID:
Molecular Weight:
24655.63 Da
  1. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007 Nov-Dec;30(8):825-30. [PubMed:18049334 ]
comments powered by Disqus
Drug created on March 19, 2008 10:16 / Updated on August 17, 2016 12:24